logo
Black dads go public with support for their kids with autism -- and each other

Black dads go public with support for their kids with autism -- and each other

Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year]
ATLANTA (AP) — When Tyrone Green's youngest son was diagnosed with autism , his wife was immediately ready to get the 3-year-old the support he needed. But Green was stuck: He had questions about his son's future and an overwhelming feeling of loneliness — like no one, not his wife, not his friends, understood his experience.
' ... (M)y wife couldn't understand what I was going through as a Black father, all these hopes and dreams I had for my kid,' said Green, who lives in Michigan. 'She didn't feel the same way.'
In 2021, he joined a Black fathers' support group and met a few other dads eager to discuss their unique challenges. They started their own podcast in 2023 called AutisHIM, a place where Black dads talk about the wins and setbacks of having autistic children.
Green is among a growing number of Black fathers of autistic children looking to be more visible in the national autism conversation through podcasts, nonprofits and summits that specifically address their experience. These men say that their hope is not only to be considered more than sidekicks to mothers of the children, but also to help other Black dads accept autism diagnoses and not prolong getting kids the help that they need.
Autism is a neurodevelopmental disorder that affects how people communicate, process information and interact with the world around them. Federal data shows that since 2020, Black children have had a higher prevalence of autism spectrum disorder than white children — a change experts credit mostly to better awareness of autism in underserved communities.
Health Secretary Robert F. Kennedy Jr. recently announced plans to have the federal government do a broad study for the causes of autism, even though it's been looked at by researchers for decades. He has said autism is a 'tragedy' that 'destroys families' and that some people with autism will never hold a job, pay taxes or go on dates.
But many people with autism live successful, socially rich and independent lives , which makes a narrative like Kennedy's dangerous, said Michael Hannon, a counseling professor at Montclair State University who studies the social and emotional aspects of autism on Black fatherhood.
It 'can literally diminish hope for any father or father figure or family,' Hannon said of Kennedy's framing of autism.
But affinity groups for Black men who have kids with autism are a successful way to get the dads to engage with their emotions, Hannon said.
'The challenge is convincing people to (talk openly and honestly), because the practice of doing that is rare, not just among Black men, but people in general,' he said, adding that people might think it will reflect on their ability to parent.
Evan Polk said a big part of navigating his 13-year-old daughter's diagnosis was learning to sit with emotions that weren't simply 'happy and mad.' In the beginning, he was very protective.
'I became a helicopter dad,' said Polk, who started AuSome Kicks, an art therapy nonprofit for autistic children near Philadelphia earlier this year. 'I didn't want nobody or nothing to harm her whatsoever. When I found out she was autistic, she'd be outside with knee pads and elbow pads looking crazy.'
He said he later taught his family to be more patient with his daughter, as opposed to traditional parenting styles of being firm and hoping that she would fall in line.
Dr. Berry Pierre said he initially was on the sidelines of his autistic daughter's support team as his wife, Maria Davis-Pierre, did the bulk of advocating.
The Florida couple founded Autism in Black and for the first five years, he said the organization didn't specifically tailor messaging to Black dads.
'Whether it be in schools, the (individual education plan) meetings, the mothers were just there.' Pierre said. 'But as we started to kind of try to go deeper and figure out 'Alright, what's going on? Where are the guys?' we started to realize that a lot of them will be there.'
Many Black dads, Pierre found out, were equally involved as the moms, and Pierre wanted to get more of them talking publicly about autism.
'The dads are there, but we know the general public doesn't realize that yet,' Pierre said. 'So we try to serve as this engine to shine a light on what's really happening. The dads are there, they're attentive. And even with this diagnosis, they're going even harder.'
Some dads, like Nicholas Love in North Carolina, said they first hesitated to openly share their journey of raising their kids with autism in fear that people may not understand.
'I was very guarded for a while in talking about my children both being on the spectrum,' said Love, who is CEO of the marketing agency The Kulur Group. 'Even in how you take pictures that you upload on social media, being cognizant and thinking about, 'Well is this a picture that looks, dare I say, the perception of what normal looks like?''
Now, he's an open book about them, is understanding when employees need a little extra time for urgent family needs and has advocated that men receive more paid leave so they will have time to be more involved with their kids.
'I got to a point where it's like, 'OK, this is my reality … I need to do my part in normalizing this,' Love said.
Green said that while his podcast and platforms like Autism in Black make it easier for Black fathers to share their stories of their kids' wins and losses, he'd like to see 'more support groups out there, more podcasts, more conversations.'
'I see a lot of Black women doing their thing and I highly appreciate that, but I think there definitely needs to be more conversations surrounding (Black fatherhood and autism) because, for myself, I'm a Black man,' Green said. 'I have a Black family, but this is never really the topic of discussion.'
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nootropics Depot's Tongkat Ali Declared Most Cost-Efficient and Potent in Industry, According to Independent Lab Tests
Nootropics Depot's Tongkat Ali Declared Most Cost-Efficient and Potent in Industry, According to Independent Lab Tests

Yahoo

time4 minutes ago

  • Yahoo

Nootropics Depot's Tongkat Ali Declared Most Cost-Efficient and Potent in Industry, According to Independent Lab Tests

TEMPE, Ariz., Aug. 4, 2025 /PRNewswire/ -- New independent UPLC laboratory testing has confirmed that Nootropics Depot's Tongkat Ali extracts are the industry's leading choice for both cost efficiency and potency, dramatically outpacing seven major competitors. This robust data, generated by advanced Ultra-Performance Liquid Chromatography (UPLC), positions Nootropics Depot as the category benchmark for quality and transparency in the Tongkat Ali supplement market. Key findings highlight: Nootropics Depot's 10% eurycomanone extract delivers 18.0mg of active eurycomanone per dollar, a 3.3x cost advantage over the nearest competitor and up to 40x more value than premium-priced brands. Its 10% extract provides 10–12mg of lab-verified eurycomanone per 100mg dose, while competitors typically yield only 0.13–4mg per dose. Cost per mg of eurycomanone for Nootropics Depot's 10% extract is just $0.06, compared to $0.20 to $5.77 from competitors, leading to as much as 96x more active compounds per dollar spent. These results are detailed in a transparent, third-party report and set a new standard for evidence-based supplement selection. "We've always believed the best way to earn customer trust is transparency," said Paul Eftang, CEO of Nootropics Depot. "This independent lab data is validation for consumers. Not only are we delivering more of Tongkat Ali's active compounds, we're setting the bar for value, potency, and scientific rigor in an industry notorious for marketing hype." "Consumers deserve clear, standardized information so they can make meaningful health decisions — not just clever branding and proprietary blends," Eftang added. "We invite every brand to publish their own lab results. This is how the industry should operate." Nootropics Depot offers three main Tongkat Ali options: Tongkat Ali 10% Tablets: Highest potency, delivering up to 12mg eurycomanone per 100mg dose. Tongkat Ali 2% Capsules: Full-spectrum, balanced option with 4mg per 200mg dose. Eurycomax Optimized Stack: Combines two extraction methods with synergistic ingredients for broader hormonal support. Additionally, the company's transparent and published testing methods allow consumers to easily compare products, moving the supplement industry toward higher standards of honesty and efficacy. Nootropics Depot is a leading supplement company setting benchmark standards for quality and transparency in the industry. Founded in 2013, Nootropics Depot's mission has been to educate consumers on the science behind dietary supplements, and to advance the lab testing and quality control standards of the industry. Their stance is that consumers should be able to trust the products they buy, and that the brands selling those products have a duty to ensure they are using modern validated science. Nootropics Depot offers a wide range of high-quality cognitive enhancement and general health supplements. The company's commitment to quality and transparency is evident in their rigorous testing procedures, easily accessible Certificates of Analysis (COAs), and lab testing results available on every product page. In addition, they have formed a Scientific Advisory Board with board certified doctors, PhD researchers, and botanists to ensure that consumers can trust that scientific rigor is being upheld in everything they do. Nootropics Depot's newly redesigned website features a user-friendly interface, and includes an innovative quiz to help beginners find the right supplements for their needs. With partnerships with third-party labs, and collaboration with the Future Nutra Foundation, Nootropics Depot continues to push the boundaries of supplement quality and consumer education. For more information about Nootropics Depot's products and their commitment to transparency, visit Media ContactMichael PackmanMarketing ManagerNootropics Depotmichael@ View original content to download multimedia: SOURCE Nootropics Depot Sign in to access your portfolio

BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology
BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology

Yahoo

time4 minutes ago

  • Yahoo

BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology

BMI OrganBank is developing novel medical devices with potential to significantly reduce the waitlist for lifesaving organ transplants, beginning with kidneys FDA Breakthrough Device Designation secures expedited FDA engagement in advance of clinical studies planned for early next year WINSTON-SALEM, N.C., Aug. 4, 2025 /PRNewswire/ -- BMI OrganBank, a pioneering leader in organ assessment and preservation, proudly announces that its revolutionary organ preservation device has received the prestigious Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This designation, granted for their kidney preservation device, underscores BMI OrganBank's commitment to advancing transformative technologies that will significantly improve outcomes for transplant patients. With current kidney perfusion technologies, which use cold storage temperatures, it is difficult to evaluate the function of kidneys before transplant. Furthermore, they are vulnerable to significant injury during the storage period before transplantation. As such, a large proportion of donated kidneys remain unused. BMI OrganBank's groundbreaking room temperature machine perfusion (RTMP) platform, developed in collaboration with leading transplant surgeons and academic medical centers, shows great promise to facilitate kidney quality assessment and extend preservation times. BMI OrganBank intends to increase the number of kidneys available for transplant and address stubbornly long kidney transplant waitlist times. A clinical study is planned for early next year. "We are incredibly honored to receive this significant designation from the FDA and look forward to working with them as we prepare for clinical studies" stated Carrie DiMarzio, Chief Executive Officer and Co-Founder. David A. Gerber, MD, abdominal transplant surgeon and Chief Medical Officer stated "We are energized by our promising preclinical data. The timing of this news is outstanding as my colleagues and I participate in the World Transplant Congress this week." About BMI OrganBank® BMI OrganBank specializes in developing transformative perfusion systems for organ and tissue evaluation and preservation. With facilities at the Innovation Quarter in Winston-Salem, NC, and Research Triangle Park, NC, the company is advancing multiple medical devices that use its patented and proprietary technologies. Its flagship product, the portable OrganBank kidney device, was co-developed with leading transplant surgeons and is set to begin clinical studies soon. Learn more at View original content to download multimedia: SOURCE BMI OrganBank Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

HCA Healthcare, Inc. (HCA): A Bull Case Theory
HCA Healthcare, Inc. (HCA): A Bull Case Theory

Yahoo

time4 minutes ago

  • Yahoo

HCA Healthcare, Inc. (HCA): A Bull Case Theory

We came across a bullish thesis on HCA Healthcare, Inc. on Valueinvesting subreddit by DividendKing47. In this article, we will summarize the bulls' thesis on HCA. HCA Healthcare, Inc.'s share was trading at $334.32 as of July 25th. HCA's trailing and forward P/E were 14.04 and 13.32 respectively according to Yahoo Finance. A successful healthcare provider smiling confidently in a modern hospital facility. HCA Healthcare, the largest U.S. hospital operator, manages 190 hospitals nationwide and plans to expand further with $5.0–5.2 billion in 2025 capital expenditures to meet growing healthcare demand. Benefiting from a healthcare services industry projected to grow at a 4.9% CAGR through 2029, HCA targets raising its 27% market share to 29% by 2030. Its 2024 revenue reached $70.6 billion, with 2025 guidance of $74–76 billion, implying 6.2% growth at the midpoint, supported by $10.5 billion in free cash flow and a $140 billion enterprise value. Growth will be driven by facility upgrades, outpatient services expansion, and technological integration, including EHRs and AI-enabled diagnostics, enhancing efficiency and patient outcomes. HCA's strategic pivot toward outpatient care, alongside modernization of existing hospitals, positions it to capture an aging population's increasing needs while mitigating inpatient reimbursement risks. Consolidation trends favor HCA's acquisition-led growth, though competitive pressures from peers like Tenet Healthcare and Universal Health Services remain. A conservative DCF analysis, using a 9% WACC and 1.25% terminal growth, values the enterprise at $167 billion, with equity of $127.5 billion or $529.79 per share—representing 58.5% upside. Risks include regulatory changes, labor shortages, and public scrutiny that could pressure margins and volumes, as well as macroeconomic headwinds that may delay elective procedures. Nonetheless, HCA's scale, robust free cash generation, and focus on operational efficiency offer resilience. Even amid industry headwinds, its expansion strategy and strong positioning provide an attractive investment opportunity, with substantial upside potential underpinned by conservative growth assumptions and disciplined capital allocation. Previously, we covered a bullish thesis on Tenet Healthcare Corporation (THC) by BlackSwanInvestor in December 2024, which highlighted operational streamlining, debt reduction, and the rapid expansion of its high-margin Ambulatory Care segment. The company's stock price has appreciated by approximately 21.7% since our coverage, as the thesis played out. The thesis still stands as Ambulatory Care growth drives value creation. DividendKing47 shares a similar view but emphasizes HCA Healthcare's scale-driven expansion and capital allocation in the same healthcare services market. HCA Healthcare, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 74 hedge fund portfolios held HCA at the end of the first quarter which was 81 in the previous quarter. While we acknowledge the potential of HCA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store